Ignyta Names CSO

San Diego-based biotechnology developer Ignyta said this morning that it has named Robert Wild, Ph.D., as the company's new Chief Scientific Officer and Senior Vice President, Research. Wild was most recently Chief Scientific Officer, Oncology Research, Drug Discovery at Eli Lilly & Company, and also has served at OSI Pharmaceuticals and Bristol-Myers Squibb. Ignyta is focused on cancer treatments.